Other WM-NET trials opening for enrollment soon are WM-NET2: Epcoritabmab for Previously Treated WM; WM-NET3: Zanubrutinib, Bendamustine, and Rituximab for Treatment-Naïve WM (ZEBRA); and WM-NET4: Pirtobrutinib, Venetoclax, and Rituximab in Previously Untreated WM. Each of these trials will enroll patients at multiple sites.
“The more institutions that join WM-NET, the easier and more convenient it will be for patients to participate in these trials,” says Newton Guerin, IWMF President and CEO. “And, the more patients we have participating in clinical trials, the more we will learn about WM, its treatment, and how we can cure it.”
If you’d like to learn more about WM-NET and participating in clinical trials, visit the Clinical Trials page on the IWMF website.
|